Syngene International, a subsidiary of BIOCON Group, Indian biotechnology major, announced today that it will offer fully integrated drug discovery services by partnering with Sapient Discovery, a US-based Biotechnology Company. Syngene provides integrated Chemistry, Biology + Biologics services to support development programs of pharmaceutical + biotech companies worldwide on a platform of confidentiality and intellectual property protection.
With world-class facilities located in a Special Economic Zone at Bangalore and a 1200 plus skilled talent pool of scientists, Syngene is equipped to partner with clients right from early stage discovery & preclinical development (Hit to Lead Programs) through clinical development (Phase I-III) till commercial manufacturing requirements for both small molecules & large molecules in the most efficient manner in terms of cost, quality & time.
With over 14 years of experience as an independent contract manufacturer & research provider, Syngene has worked with companies of all sizes from small university spin-offs to major research institutes, government agencies, hospitals, small, medium & large established biopharmaceutical, agrochemical & chemical companies by employing flexible & customized business models as per requirement of the work. The company is also leveraging the convergence of IT and biotech. It also conducts high value R&D in early stage drug discovery and development for a diverse global clientele.
Sapient Discovery is an established leader in structure-guided drug Discovery Company with a number of proprietary algorithms and capabilities for efficient protein structure based drug discovery and optimization. Sapient Discovery’s proprietary Genes-to-Leads® technology incorporates knowledge of the dynamically flexible 3-D structures of drug targets and “anti- targets” – proteins exhibiting structural similarity to the drug target – with laboratory screening methods, to generate target-selective initial drug leads in as little as 60 days.
“Sapient Discovery’s proprietary Genes-to-Leads®, Fragments-to-Leads® and X-ray crystallography technologies provide dramatic reductions in the time and costs associated with compound synthesis and screening and expands the horizons of chemical diversity potentially applicable to novel or even well studied drug targets,” according to Kal Ramnarayan, Ph.D., President and CSO of Sapient Discovery. He also added that Sapient Discovery’s Fragments-to-Leads® assures the novelty of identified lead molecules for protein targets, since the 10,000 plus fragment collection at Sapient Discovery can aid in the ultimate synthesis of novel, patentable lead molecules in a short time span.
“The challenges posed by the rapidly growing number of new drug targets will be greatly benefited by the integration of supercomputer-based virtual screening and X-ray crystallography methods with laboratory screening technologies. These techniques are likely to play an increasingly important role in drug discovery and optimization in the future,” said Dr. Goutam Das, COO of Syngene International.
The companies intend to provide a highly integrated platform for structure-based drug discovery with one stop shop for structure-guided discovery, chemistry, biology and structural biology capabilities. This arrangement is crucial at a time when cost-reductions and efficiency in the drug discovery process is driving companies to look for suitable out-sourcing partners.